Darolutamide and Survival in mHSPC
Oncología

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Matthew R. Smith, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142.

Related Content
Darolutamide + ADT + Docetaxel in mHSPC by Subgroups
CPHSm
Informe SEOM de evaluación de darolutamida en CPRCnm
CPRCnm
Treatment of nmCRPC: comorbidities and DDIs
CPRCnm